Price
$2.35
Increased by +0.86%
Dollar Volume (20D)
4.57 M
ADR%
9.76
Earnings Report Date (estimate)
Mar 13, 24
Shares Float
25.75 M
Shares Outstanding
82.05 M
Shares Short
4.75 M
Market Cap.
191.18 M
Beta
1.74
Price / Earnings
N/A
20D Range
2.26 3.62
50D Range
1.42 3.77
200D Range
1.1 7.28
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 23 -1.16
Decreased by -118.87%
-0.74
Decreased by -56.76%
Aug 9, 23 -0.75
Decreased by -33.93%
-0.68
Decreased by -10.29%
May 9, 23 -0.72
Decreased by -820%
-0.69
Decreased by -4.35%
Mar 15, 23 -0.72
Decreased by -53.19%
-0.28
Decreased by -157.14%
Nov 8, 22 -0.53
Decreased by -20.45%
-0.53
Aug 10, 22 -0.56
Decreased by -64.71%
-0.45
Decreased by -24.44%
May 12, 22 0.1
Increased by +112.2%
-0.18
Increased by +155.56%
Mar 15, 22 -0.47
Decreased by -2.17%
-0.42
Decreased by -11.9%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-49.88 M
Decreased by -137.47%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-32.4 M
Decreased by -44.86%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by -100%
-29.63 M
Decreased by -741.55%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 -24.99 M
Decreased by -557.02%
-28.1 M
Decreased by -77.72%
Increased by +112.46%
Increased by +138.89%
Sep 30, 22 0
Decreased by -100%
-21.01 M
Decreased by -49.91%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by -100%
-22.37 M
Decreased by -106.09%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 24.99 M
Increased by +727.73%
4.62 M
Increased by +121.66%
Increased by +18.48%
Decreased by -96.55%
Dec 31, 21 5.47 M
Increased by +1.07%
-15.81 M
Decreased by -76.52%
Decreased by -289.19%
Decreased by -74.65%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.